Status:
COMPLETED
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)
Lead Sponsor:
Gemin X
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogeneic signal is present. Obatoclax is designed to restore apoptosis through inhibition...
Eligibility Criteria
Inclusion
- Pathological confirmation of Myelodysplastic Syndromes (MDS)
- Patients must have had no prior systemic therapy
- Must have normal organ functions
- Must have the ability to understand and willingness to sign a written informed consent form
Exclusion
- Must not be a result of prior chemotherapy and/or radiotherapy for another malignancy
- No other agents or therapies administered in the intent to treat
- Uncontrolled, intercurrent illness
- Pregnant women and women who are breast feeding
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00413114
Start Date
December 1 2006
End Date
November 1 2009
Last Update
August 26 2013
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 00000
2
Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
3
James A. Haley Veterans Hospital
Tampa, Florida, United States, 33612
4
Emory University School of Medicine/ Winship Cancer Center
Atlanta, Georgia, United States, 30322